From MarketBeat:



An insider at RAPT Therapeutics, Inc. sold 2,500 shares of the company’s stock on December 21st. The shares were sold at an average price of $21.68, totaling $54,200. This follows earlier sales of 1,500 shares in November and 2,500 shares in October. After the recent sale, the insider still holds 15,020 shares of the company valued at approximately $325,633.60. The company’s stock has been performing well, trading at $23.57 on Friday. Following the recent quarterly earnings report that showed a negative earnings per share, analysts predict an overall negative earnings per share for the year. Despite this, RAPT Therapeutics has received positive ratings from nine analysts, with an average price target of $37.50. Institutional investors also own a significant portion of the company’s stock. RAPT Therapeutics focuses on developing small molecule therapies for oncology and inflammatory diseases, with its lead inflammation drug candidate being RPT193, a CCR4 antagonist. Furthermore, MarketBeat has identified five stocks that top analysts are recommending, excluding RAPT Therapeutics.



Original: William Ho Sells 2,500 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stock